KR890000664B1 - 미분된 베클로메타손 디프로피오네이트 일수화물의 제조방법 - Google Patents

미분된 베클로메타손 디프로피오네이트 일수화물의 제조방법 Download PDF

Info

Publication number
KR890000664B1
KR890000664B1 KR8204671A KR820004671A KR890000664B1 KR 890000664 B1 KR890000664 B1 KR 890000664B1 KR 8204671 A KR8204671 A KR 8204671A KR 820004671 A KR820004671 A KR 820004671A KR 890000664 B1 KR890000664 B1 KR 890000664B1
Authority
KR
South Korea
Prior art keywords
beclomethasone dipropionate
water
monohydrate
finely divided
particle size
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
KR8204671A
Other languages
English (en)
Korean (ko)
Other versions
KR840002007A (ko
Inventor
해롤드 헌트 죤
말콜름 패드필드 죤
Original Assignee
바리 안소니 뉴우샘
글락소 그룹 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바리 안소니 뉴우샘, 글락소 그룹 리미티드 filed Critical 바리 안소니 뉴우샘
Publication of KR840002007A publication Critical patent/KR840002007A/ko
Application granted granted Critical
Publication of KR890000664B1 publication Critical patent/KR890000664B1/ko
Expired legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
    • C07J5/0069—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
    • C07J5/0076—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group by an alkyl group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
KR8204671A 1981-10-19 1982-10-16 미분된 베클로메타손 디프로피오네이트 일수화물의 제조방법 Expired KR890000664B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8131425 1981-10-19
GB8131425 1981-10-19

Publications (2)

Publication Number Publication Date
KR840002007A KR840002007A (ko) 1984-06-11
KR890000664B1 true KR890000664B1 (ko) 1989-03-22

Family

ID=10525238

Family Applications (1)

Application Number Title Priority Date Filing Date
KR8204671A Expired KR890000664B1 (ko) 1981-10-19 1982-10-16 미분된 베클로메타손 디프로피오네이트 일수화물의 제조방법

Country Status (22)

Country Link
US (1) US4866051A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS5890599A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR890000664B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU551471B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE894725A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1189853A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH (1) CH652134A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE3238569A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK168389B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DO (1) DOP1990004774A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES8404374A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI73128C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR2514769B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK100989A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE54170B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IT (1) IT1196553B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY8700910A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL8204013A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ202212A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT75692A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SE (1) SE454356B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA827601B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766573A (en) * 1988-12-06 1998-06-16 Riker Laboratories, Inc. Medicinal aerosol formulations
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5208226A (en) * 1989-09-08 1993-05-04 Glaxo Group Limited Medicaments
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
US5439670A (en) * 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
SE9101090D0 (sv) * 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
GB9202519D0 (en) * 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
NZ257212A (en) 1992-09-29 1996-11-26 Inhale Therapeutic Syst Parathyroid hormone formulations comprising a biologically active n-terminal fragment of the hormone
GB9322014D0 (en) * 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
PE44995A1 (es) * 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
BR9507023A (pt) 1994-03-07 1997-09-23 Inhale Therapeutic Syst Processos para aerossolização de uma dose de insulina para a liberação respiratória de insulina e para preparação de uma composição de insulina e composição de insulina
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6428771B1 (en) * 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
WO1997001341A1 (en) * 1995-06-29 1997-01-16 Mcneil-Ppc, Inc. The combination of topical nasal mast cell stabilizers and topical nasal steroids
US5987746A (en) * 1996-02-21 1999-11-23 Medtronic, Inc. Method of making medical electrical lead
US20030203036A1 (en) 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
GB9826284D0 (en) * 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
EP2280020B1 (en) * 1999-06-29 2016-02-17 MannKind Corporation Pharmaceutical formulations comprising a peptide complexed with a diketopiperazine
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
MXPA02001323A (es) 2000-05-10 2004-07-16 Alliance Pharma Microgranulos con base fosfolipida para la liberacion de farmaco.
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7575761B2 (en) 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
EP1311294A2 (en) * 2000-08-04 2003-05-21 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
JP4837892B2 (ja) 2001-11-01 2011-12-14 ネクター セラピューティクス 粉末バッチを製造する方法
ATE508735T1 (de) 2001-12-19 2011-05-15 Novartis Ag Pulmonale verabreichung von aminoglykosiden
ES2425392T3 (es) 2002-03-20 2013-10-15 Mannkind Corporation Cartucho para un aparato de inhalación
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
AU2003277589A1 (en) * 2002-11-08 2004-06-15 Kaneka Corporation Method of separating ergosterol
US7338171B2 (en) * 2003-10-27 2008-03-04 Jen-Chuen Hsieh Method and apparatus for visual drive control
JP2007517892A (ja) * 2004-01-12 2007-07-05 マンカインド コーポレイション ２型糖尿病における血清プロインスリンレベルを低下させる方法
US20080090753A1 (en) * 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
JP5078014B2 (ja) 2004-08-20 2012-11-21 マンカインド コーポレイション ジケトピペラジン合成の触媒反応
PL2322180T3 (pl) 2004-08-23 2015-10-30 Mannkind Corp Sole diketopiperazyny do dostarczania leków
US20060204601A1 (en) * 2005-03-09 2006-09-14 Palu Afa K Formulations and methods for preventing and treating substance abuse and addiction
JP2008533055A (ja) * 2005-03-18 2008-08-21 ナノマテリアルズ テクノロジー ピーティーイー リミテッド 吸入剤
CN104324366B (zh) 2005-09-14 2016-10-05 曼金德公司 以提高活性试剂对结晶微粒表面的亲和力为基础的药物配制方法
US8084420B2 (en) * 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US7713929B2 (en) 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
WO2007041481A1 (en) * 2005-09-29 2007-04-12 Biodel, Inc. Rapid acting and prolonged acting insulin preparations
KR20080096809A (ko) 2006-02-22 2008-11-03 맨카인드 코포레이션 디케토피페라진 및 활성제를 포함하는 마이크로입자의 약학특성의 개선 방법
CA2649109A1 (en) * 2006-04-12 2007-10-25 Biodel, Inc. Rapid acting and long acting insulin combination formulations
UY30543A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de beta- agonistas
UY30542A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de agonistas beta
MX2009008582A (es) 2007-02-11 2009-10-30 Map Pharmaceuticals Inc Metodo para la administracion terapeutica de dihidroergotamina para permitir un rapido alivio de la migraña mientras se minimiza el perfil de efectos secundarios.
WO2008124522A2 (en) * 2007-04-04 2008-10-16 Biodel, Inc. Amylin formulations
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
CA2711561A1 (en) * 2008-01-04 2009-07-16 Biodel, Inc. Insulin formulations for insulin release as a function of tissue glucose levels
GB0806873D0 (en) * 2008-04-16 2008-05-21 Breath Ltd Steroid nebuliser formulation
MY155524A (en) 2008-06-13 2015-10-30 Mannkind Corp A dry powder inhaler and system for drug delivery
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
KR101628410B1 (ko) 2008-06-20 2016-06-08 맨카인드 코포레이션 흡입 활동에 관한 실시간 프로파일링을 위한 대화형 장치 및 방법
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
DK2405963T3 (da) 2009-03-11 2013-12-16 Mannkind Corp Apparat, system og fremgangsmåde til at måle modstand i en inhalator
KR20180079458A (ko) 2009-06-12 2018-07-10 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
GB0914231D0 (en) * 2009-08-14 2009-09-30 Breath Ltd Dry powder inhaler formulations
US9016147B2 (en) 2009-11-03 2015-04-28 Mannkind Corporation Apparatus and method for simulating inhalation efforts
BR112012033060A2 (pt) 2010-06-21 2018-02-27 Mannkind Corp métodos de sistema de liberação de fármaco em pó seco
AU2012236150B2 (en) 2011-04-01 2016-03-31 Mannkind Corporation Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
AU2012328885B2 (en) 2011-10-24 2017-08-31 Mannkind Corporation Methods and compositions for treating pain
SG10201605800UA (en) 2012-07-12 2016-09-29 Mannkind Corp Dry powder drug delivery system and methods
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
AU2014228415B2 (en) 2013-03-15 2018-08-09 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
KR102465025B1 (ko) 2013-07-18 2022-11-09 맨카인드 코포레이션 열-안정성 건조 분말 약제학적 조성물 및 방법
WO2015021064A1 (en) 2013-08-05 2015-02-12 Mannkind Corporation Insufflation apparatus and methods
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
CN112997256A (zh) 2018-06-14 2021-06-18 阿斯利康(英国)有限公司 使用皮质类固醇医药组合物治疗和预防哮喘症状的方法
IT201800007527A1 (it) * 2018-07-26 2020-01-26 Sofar Spa Composizione contenente beclometasone per la prevenzione e il trattamento di prostatiti batteriche e vaginiti

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1047519A (en) * 1963-06-11 1966-11-02 Glaxo Lab Ltd 17ª‡,21-diesters of 11,17,21-trihydroxy steroid compounds
GB1429184A (en) * 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
DK153556C (da) * 1974-03-27 1988-12-05 Plurichemie Anstalt Fremgangsmaade til fremstilling af estere af 9alfa-klor- eller -fluor-16alfa- eller -16beta-metyl-21-desoxyprednisoloner
GB1571629A (en) * 1977-11-30 1980-07-16 Fisons Ltd Pharmaceutical compositions containing beclomethasone dipropionate
IT1121513B (it) * 1979-05-28 1986-04-02 Chiesi Farma Spa Processo per la conversione di umo steroide antiinfiammatorio in una forma suscettibile di essere somministarta come aerosol
EP0039369B1 (en) * 1980-05-02 1983-06-15 Schering Corporation Beclomethasone ester solvates, process for their preparation, and preparation of a formulation
FI63672C (fi) * 1980-05-19 1983-08-10 Orion Yhtymae Oy Foerfarande foer framstaellning av en blandning av beklometasondipropionat och triklorfluormetan eller diklordifluormetan
PT71309A (en) * 1980-05-27 1980-06-01 Hovione Sociedade Quimica Lda Process of selective
PT73772B (en) * 1980-10-06 1983-10-14 Glaxo Group Ltd Topically administrable pharmaceutical compositions containing anti-inflammatory steroids
US4391755A (en) * 1982-01-18 1983-07-05 E. R. Squibb & Sons, Inc. Steroid monohydrates, formulations containing same and method
IL75903A (en) * 1984-07-25 1989-10-31 Hovione Int Ltd Di-isopropyl ether solvates of beclomethasone 17,21-dipropionate,their preparation and use
GB8432063D0 (en) * 1984-12-19 1985-01-30 Riker Laboratories Inc Physically modified steroids

Also Published As

Publication number Publication date
DE3238569C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1991-01-31
FI73128C (fi) 1987-09-10
ES516611A0 (es) 1984-05-01
IT8249294A0 (it) 1982-10-18
BE894725A (fr) 1983-04-18
JPS5890599A (ja) 1983-05-30
ZA827601B (en) 1983-09-28
FI823561A0 (fi) 1982-10-18
DE3238569A1 (de) 1983-05-05
AU551471B2 (en) 1986-05-01
SE8205904L (sv) 1983-04-20
AU8946082A (en) 1984-05-03
FR2514769B1 (fr) 1985-08-30
DK168389B1 (da) 1994-03-21
IT1196553B (it) 1988-11-16
DOP1990004774A (es) 1996-02-02
DK461182A (da) 1983-04-20
JPH0424358B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1992-04-24
HK100989A (en) 1989-12-29
ES8404374A1 (es) 1984-05-01
NL8204013A (nl) 1983-05-16
FI823561L (fi) 1983-04-20
FR2514769A1 (fr) 1983-04-22
PT75692A (en) 1982-11-01
CA1189853A (en) 1985-07-02
SE454356B (sv) 1988-04-25
KR840002007A (ko) 1984-06-11
IE822514L (en) 1983-04-19
CH652134A5 (de) 1985-10-31
MY8700910A (en) 1987-12-31
FI73128B (fi) 1987-05-29
IE54170B1 (en) 1989-07-05
US4866051A (en) 1989-09-12
SE8205904D0 (sv) 1982-10-18
NZ202212A (en) 1986-01-24

Similar Documents

Publication Publication Date Title
KR890000664B1 (ko) 미분된 베클로메타손 디프로피오네이트 일수화물의 제조방법
US4364923A (en) Chemical compounds
KR100348120B1 (ko) 물질의콘디셔닝방법
US6287540B1 (en) Formulation for inhalation
US20050207989A1 (en) High storage stability inhalable compositions
CN100398095C (zh) 用于吸入的含有微粒化结晶活性组分的无菌含水悬浮液的制备
CA1075228A (en) Flunisolide to treat respiratory diseases
EP0039369A1 (en) Beclomethasone ester solvates, process for their preparation, and preparation of a formulation
AU2001259007A1 (en) Novel composition
GB2107715A (en) Micronised beclomethasone dipropionate monohydrate and powder inhalation compositions containing it
CZ295083B6 (cs) Suchý práškový prostředek s obsahem budesonidu, způsob jeho přípravy a léčivo s jeho obsahem
US6391340B1 (en) Dry powder pharmaceutical formulation
KR20200117056A (ko) 플루티카손 프로피오네이트 형태 1의 제조 방법
KR880001237B1 (ko) 베클로메타손 17,21-디프로피오네이트의 용매화합물의 제조방법
KR101066801B1 (ko) 항콜린제를 함유하는 ｈｆａ- 현탁 제형
JP5147158B2 (ja) 無水物のｈｆａ懸濁製剤
DE10209243A1 (de) Neue Arzneimittelkombination zur Inhalation
JPH0129199B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19821016

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19870901

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19821016

Comment text: Patent Application

PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19880725

Patent event code: PE09021S01D

PG1605 Publication of application before grant of patent

Comment text: Decision on Publication of Application

Patent event code: PG16051S01I

Patent event date: 19890120

PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19890531

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19890619

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19890619

End annual number: 3

Start annual number: 1

PR1001 Payment of annual fee

Payment date: 19920313

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 19930309

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 19940304

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 19950309

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 19960315

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 19970312

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 19970827

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 19990311

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20000308

Start annual number: 12

End annual number: 12

PR1001 Payment of annual fee

Payment date: 20010310

Start annual number: 13

End annual number: 13

PR1001 Payment of annual fee

Payment date: 20020314

Start annual number: 14

End annual number: 14

PC1801 Expiration of term